This site complies with the HONcode standard for trustworthy health information:
verify here.

Rewarding for
you and us
Defeat Diabetes Foundation

Defeat Diabetes
Foundation
150 153rd Ave,
Suite 300
Madeira Beach, FL 33708

Research » Drugs

Search our News Articles Archives for diabetes and health news. Search by word or phrase. The latest article will appear first.

Diabetes Medication May Promote Eye Health

Posted: Wednesday, June 25, 2008

The diabetes medication rosiglitazone has been associated with a reduction in the likelihood of developing the eye disease called proliferative diabetic retinopathy. A study published in the June issue of Archives of Ophthalmology also found that diabetes patients using the drug were less likely to have reductions in visual acuity (or sharpness).

More Evidence of Increased Fractures With Thiazolidinediones

Posted: Wednesday, June 25, 2008

Further evidence that long-term use of the thiazolidinediones rosiglitazone and pioglitazone may increase risk of fractures (particularly of the hip and wrist) has come from a new case-control study.

No Efficacy or Safety Sacrifice with Weekly Exenatide (Byetta LAR)

Posted: Friday, June 20, 2008

A long-acting version of the injectable diabetes drug exenatide (Byetta) showed efficacy advantages and safety comparable to the standard formulation given twice a day, researchers said.

HEART2D Study Shows No Cardiovascular Benefit by Targeting Postprandial Glucose Levels

Posted: Friday, June 20, 2008

A study examining the effects of hyperglycemia on type 2 diabetes patients after acute myocardial infarction (AMI), the Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes (HEART2D) study, found no cardiovascular benefits from tightly controlling postprandial variations in blood glucose.

Further Evidence Supports Vitamin-D-Deficiency Link to CHD

Posted: Friday, June 20, 2008

Further evidence that vitamin-D deficiency may increase the risk of heart disease has come from a new case-control study.

Investigational DPP-4 Inhibitor Effective as Add-On and Stand-Alone

Posted: Friday, June 20, 2008

Alogliptin, an investigational once-daily oral drug for type 2 diabetes, showed good efficacy and safety both as monotherapy and together with standard agents, researchers in five phase III trials stated at ADA Scientific Sessions.

Glycemic Control Markedly Improved with Duodenal-Jejunal Sleeve

Posted: Friday, June 20, 2008

For obese patients with diabetes, a Teflon-like sleeve placed inside the small intestine just beyond the stomach iimproves glycemic control quickly and markedly.

Diabetic Ulcer Gel Gets Black Box Warning

Posted: Friday, June 20, 2008

A black box warning has been added to the safety labeling for becaplermin gel (Regranex, Johnson & Johnson) to warn of the increased risk for cancer mortality in patients who use 3 or more tubes of the product, the US Food and Drug Administration (FDA) announced on Friday.

Diabetes Prevention Hopes Revived for Thiazolidinedione

Posted: Friday, June 20, 2008

Pioglitazone (Actos) may prevent or delay progression to diabetes for patients with pre-diabetes by 81%, researchers found.

Two Genes Connected to Autoimmune Diseases

Posted: Monday, June 16, 2008

The location on a chromosome of two specific genes has been shown to play a major role in the development of autoimmune diseases. This discovery could help develop future treatments and therapies for autoimmune diseases, such as type 1 diabetes.